Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Novavax, Inc. (NASDAQ:NVAX) Q1 2024 Earnings Call Transcript May 12, 2024 Novavax, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Novavax’ First Quarter 2024 Financial Results and Operational Highlights Conference Call. All lines will […]